Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Intra-Cellular Therapies, Inc. ITCI

Set alert

Price alert · ITCI

All alert types
131.87 0.00 0.00%

At close · Apr 2

131.87 Day range 131.87

52-week range unavailable

YTD
+57.89%
1 year
+97.80%
Open
131.87
Prev close
131.87
Mkt cap
14.05B
Vol
16.04M
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
131.87
High
131.87
Forward P/E
507.19
Beta
0.46
Short ratio
1.20
Inst. own
96.45%
Dividend
0.00
Ex-div date
50-d avg
129.34
200-d avg
93.12
1y target
132.00

6M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Jan 14, 2025Downgrade: Piper Sandler · Overweight → Neutral
  • Jan 22, 2025Downgrade: RBC Capital · Outperform → Sector Perform
  • Jan 31, 2025Downgrade: Canaccord Genuity · Buy → Hold
  • Feb 21, 2025Rating: Needham · Hold → Hold
  • Feb 24, 2025Downgrade: Mizuho · Outperform → Neutral
  • Apr 2, 2025Rating: Cantor Fitzgerald · Neutral → Neutral
Signals (12)
NameDateAgo
MACD: Sell SignalJan 31, 20251 year ago
SMA: BullishJan 10, 20251 year ago
MACD: Buy SignalJan 10, 20251 year ago
RSI: OverboughtJan 10, 20251 year ago
SMA: BearishDec 30, 20241 year ago
MACD: Sell SignalNov 15, 20241 year ago
RSI: OverboughtOct 30, 20242 years ago
SMA: BullishOct 15, 20242 years ago
SMA: BearishOct 14, 20242 years ago
SMA: BullishOct 11, 20242 years ago
MACD: Buy SignalOct 11, 20242 years ago
SMA: BullishOct 9, 20242 years ago

Analyst view

Consensus: hold

Hold
Price target (mean) 132.00
Ratings (0m) 7 2 buy · 5 hold · 0 sell
  • Strong buy1
  • Buy1
  • Hold5
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 7
  • 1 month ago 12
  • 2 months ago 13
  • 3 months ago 13

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ITCI analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.10-0.16 – -0.04-0.16+37.5%205.61M+41.9%4
Next quarter0.015-0.07 – 0.11-0.16+109.4%225.73M+39.9%4
Current year0.15-0.38 – 0.83-0.72+120.8%959.34M+40.9%5
Next year3.130.87 – 5.360.15+1984.1%1.42B+47.8%6

Upgrades and downgrades

The latest rating changes

ITCI analyst upgrades and downgrades
DateFirmActionFromTo
Apr 2, 2025Cantor FitzgeraldReiteratedNeutralNeutral
Feb 24, 2025MizuhoDowngradeOutperformNeutral
Feb 21, 2025NeedhamReiteratedHoldHold
Jan 31, 2025Canaccord GenuityDowngradeBuyHold
Jan 22, 2025RBC CapitalDowngradeOutperformSector Perform
Jan 14, 2025Piper SandlerDowngradeOverweightNeutral
Jan 13, 2025NeedhamDowngradeBuyHold
Nov 4, 2024JP MorganMaintainedOverweightOverweight
Oct 31, 2024NeedhamReiteratedBuyBuy
Oct 30, 2024NeedhamReiteratedBuyBuy
Oct 11, 2024Morgan StanleyMaintainedOverweightOverweight
Oct 4, 2024RBC CapitalMaintainedOutperformOutperform
Sep 20, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Sep 16, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Sep 6, 2024Piper SandlerUpgradeNeutralOverweight
Aug 21, 2024JP MorganMaintainedOverweightOverweight
Aug 8, 2024RBC CapitalMaintainedOutperformOutperform
Aug 8, 2024Cantor FitzgeraldMaintainedOverweightOverweight
Aug 8, 2024UBSMaintainedNeutralNeutral
Aug 8, 2024Goldman SachsMaintainedNeutralNeutral
Aug 8, 2024NeedhamReiteratedBuyBuy
Aug 7, 2024NeedhamReiteratedBuyBuy
Jul 22, 2024NeedhamMaintainedBuyBuy
Jun 25, 2024UBSDowngradeBuyNeutral
Jun 25, 2024RBC CapitalReiteratedOutperformOutperform
Jun 21, 2024MizuhoMaintainedBuyBuy
Jun 20, 2024Canaccord GenuityMaintainedBuyBuy
Jun 18, 2024NeedhamMaintainedBuyBuy
Jun 14, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Jun 12, 2024JP MorganMaintainedOverweightOverweight